Vol 8, Supplement 1 (October 22, 2019): Chinese Clinical Oncology

Editorial

Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets
Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial
Francesco Facchinetti, Marcello Tiseo
Does bisphosphonate treatment reduce the risk of future cancer?
Michael Pazianas, Bo Abrahamsen
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC
Tianhong Li, Weijie Ma, Eddie C. Tian
Perineural invasion in oral cancer: challenges, controversies and clinical impact
Sabrina Daniela da Silva, Luiz Paulo Kowalski
Recent changes in the American Joint Commission Cancer staging of human papilloma virus related oropharyngeal cancer: validating the present and envisioning the future
Brett A. Miles
The dawn of a universal language for an emerging malignancy
Junichi Shindoh
The 8th Edition of the American Joint Committee on Cancer (AJCC8) Staging Manual: any improvement in the prognostication of oral tongue cancer?
Alhadi Almangush, Tuula Salo
Considering sarcoma staging systems and their implications to personalized care
Rick L. Haas, Michiel A. J. van de Sande
Occult breast cancer: the uncommon presentation of a common disease
Angela Toss, Luca Moscetti, Stefano Cascinu
Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview
Jennifer K. Plichta
Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?
William W. Tseng, Sandro Pasquali, James S. Hu, Lawrence R. Menendez, Alessandro Gronchi
Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer
Swaroop Revannasiddaiah, Ishu Gupta, Santhosh Kumar Devadas
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Francesco Ricci, Christophe Le Tourneau
What can National Registry data tell us about occult breast cancer?
John Benjamin Wild, Steven Thrush, Raghavan Vidya
Impact of hypochloremia in resected colorectal cancer patients
Mai Tsutsui, Seiichiro Yamamoto
A step ahead on CTHRC1, and not just reinventing the wheel!
Siddharth Turkar, Anant Ramaswamy, Vikas Ostwal

Editorial Commentary

Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications
Luiz Paulo Kowalski, Hugo Fontan Köhler
AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?
Daniel H. Ahn, Tanios Bekaii-Saab
Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe
Adam Garsa, Jennifer C. Ho, Chaosu Hu, Eric L. Chang
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Veronica Mollica, Vincenzo Di Nunno, Francesco Massari
Chemotherapy of pancreatic cancer in patients with poor performance
Dominik Schulz, Hana Algül
Perioperative safety in patients with resectable synchronous colorectal liver metastases
Lucas D. Lee, Y. Nancy You
Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy
Shawn Kothari, Everett E. Vokes
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
Ibrahim Aldoss, Guido Marcucci
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
Ariane Vieira Scarlatelli Macedo, Eduardo Ramacciotti

Disclosure:

The supplement was published without any sponsorship or funding.